Hepatic arterial infusion of CAR-T cells
AssigneeProspect Chartercare Rwmc, LLC
InventorsSteven C. Katz, Richard Junghans
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.
Claims15
A method for treating a liver metastasis in a human subject, comprising:
- percutaneously infusing into the hepatic artery of the human subject a therapeutically effective amount of a composition comprising a chimeric antigen receptor T cell (CAR-T cell) which expresses a chimeric antigen receptor protein, wherein the chimeric antigen receptor protein binds to an antigen expressed on metastatic cells in the liver, wherein the chimeric antigen receptor protein comprises SEQ ID NO:
- 1.
A method for treating a liver metastasis in a human subject, comprising:
- percutaneously infusing into the hepatic artery of the human subject a composition comprising a CAR-T cell which expresses a chimeric antigen receptor protein (CAR), wherein the CAR protein binds to CEA, wherein the chimeric antigen receptor protein comprises SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.